STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Oruka Therapeutics reported that 63% of trial participants achieved complete skin clearance with ORKA‑001 in a mid‑stage study.
- ORKA‑001 showed blood‑exposure levels that support a once‑per‑year injection schedule.
- Skyrizi is a blockbuster biologic whose remission rates ORKA‑001 could match or exceed with a once‑yearly injection.
- Bimzelx is another leading psoriasis drug that could be challenged by ORKA‑001’s annual dosing schedule.
Why it matters: Patients with plaque psoriasis stand to gain a once‑yearly injection that cleared skin in 63% of trial participants, while competitors Skyrizi and Bimzelx risk losing market share as insurers favor the cheaper, less‑frequent regimen.
Ask SkimNews
